Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. AUTHORS: Read More

2024-03-25T11:24:02-07:00June 1st, 2019|Adjuvant, BluePrint, Evidence, MammaPrint, WSG-PRIMe|

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

PUBLICATION: Breast Cancer Res Treat (2017) 166: 593. AUTHORS: Read More

2024-03-25T08:59:17-07:00November 1st, 2017|Endocrine, Evidence, MammaPrint, STO-3|

Genomic Profiling of Breast Cancer in African-American Women Using MammaPrint.

PUBLICATION: Breast Cancer Res Treat (2016) 159: 481. AUTHORS: Read More

2024-03-25T09:17:41-07:00August 27th, 2016|Evidence, MammaPrint, Other, Racial Disparities|

Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups

PUBLICATION: Breast Cancer Res Treat (2015) 154: 81. AUTHORS: Read More

2024-03-25T09:23:03-07:00November 1st, 2015|BluePrint, Evidence, Other|

Gene Expression Profiling to Predict the Risk of Locoregional Recurrence in Breast Cancer: A Pooled Analysis

PUBLICATION: Breast Cancer Res Treat (2014) 148: 599. AUTHORS: Read More

2024-03-25T09:27:24-07:00November 24th, 2014|Adjuvant, Evidence, MammaPrint|

Optimized Outcome Prediction in Breast Cancer by Combining the 70-Gene Signature with Clinical Risk Prediction Algorithms

PUBLICATION: Breast Cancer Res Treat. 2014 Jun;145(3):697-705. doi: 10.1007/s10549-014-2954-2. Epub Read More

2024-03-25T10:21:40-07:00June 1st, 2014|Adjuvant, Evidence, MammaPrint, RASTER|
Go to Top